Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 14

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
 Liabilities, Noncontrolling Interest and Stockholders’ Equity$1,380,612 $1,139,802  

The accompanying notes are an integral part of these unaudited consolidated financial statements. 

1

Arrowhead Pharmaceuticals, Inc.

Consolidated Statements of Operations and Comprehensive (Loss) Income

(in thousands, except per share amounts)

(unaudited) 

Three Months Ended June 30,Nine Months Ended June 30,2025202420252024Revenue$27,767 $— $572,976 $3,551 Operating expenses:Research and development162,368 152,431 432,472 370,044 General and administrative30,949 23,710 86,264 72,384 Total operating expenses193,317 176,141 518,736 442,428 Operating (loss) income(165,550)(176,141)54,240 (438,877)Other (expense) income:Interest income11,019 6,498 28,236 15,550 Interest expense(24,382)(5,094)(67,667)(17,705)Other, net(176)760 603 1,370 Total other (expense) income(13,539)2,164 (38,828)(785) (Loss) income before income tax expense and noncontrolling interest(179,089)(173,977)15,412 (439,662)Income tax (benefit) expense(437)— 1,419 (3,313)Net (loss) income including noncontrolling interest$(178,652)$(173,977)$13,993 $(436,349)Net loss attributable to noncontrolling interest, net of tax(3,411)(3,184)(8,126)(7,392)Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.$(175,241)$(170,793)$22,119 $(428,957)Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:Basic$(1.26)$(1.38)$0.17 $(3.63)Diluted$(1.26)$(1.38)$0.17 $(3.63)Weighted-average shares used in calculatingBasic139,039 124,199 132,385 118,260 Diluted139,039 124,199